Pharma companies directory 2026

Pharmaceutical Companies in Australia

Australia is a high-regulation, high-subsidy medicines market in which a product that is on the Australian Register of Therapeutic Goods but not on the Pharmaceutical Benefits Scheme is, for most patients, only half launched.

The Therapeutic Goods Administration decides whether a medicine may be sold. The Pharmaceutical Benefits Advisory Committee then decides whether the Commonwealth will subsidise it, and the Department of Health, Disability and Ageing administers the PBS that, in 2024–25, spent AUD 19.1 billion of government money on 226 million subsidised prescriptions across 949 listed medicines. Patient copayments are capped — the general maximum fell to AUD 25 from January 2026 — so originator economics live or die in the PBAC dossier, not at the pharmacy till. CSL, headquartered in Melbourne, is the country’s global plasma and vaccine champion; its Seqirus arm supplies influenza vaccine at home and abroad. Mayne Pharma and Viatris’s Alphapharm plant give Australia a generics manufacturing base. Pfizer, GSK, AstraZeneca, Novartis, Roche, Sanofi, MSD, Janssen, Amgen and Bristol Myers Squibb run the innovator affiliates that fill most of the high-value PBS oncology and immunology lines. BioNixus keeps this roster current for any access or brand-share brief that has to survive a Sydney, Melbourne or Brisbane P&T committee.

Updated September 2026 · Therapeutic Goods Administration — Australian Register of Therapeutic Goods and licensed manufacturers as of September 2026 · 18 named accounts

Request a proposal for Australia Browse the 18 companies

AUD 19.1bn

Commonwealth PBS expenditure on medicines, 2024–25 (up 7.4% on 2023–24)

226m

PBS-subsidised prescriptions dispensed in 2024–25

949

Distinct medicines listed on the PBS at 30 June 2025 (5,164 brands)

AUD 25

Maximum general PBS copayment from January 2026 (down from AUD 31.60)

Named accounts

Top pharmaceutical companies in Australia

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Therapeutic Goods Administration — Australian Register of Therapeutic Goods and licensed manufacturers (as of 2026-09-04).

#	Company	HQ	Type	Therapeutic focus	Notes
01	Therapeutic Goods Administration (TGA)	Canberra	Government	ARTG registration, GMP and post-market safety	The regulator whose pathway choice — standard, priority, provisional, Access Consortium — sets the clock before any PBS conversation can start.
02	Department of Health, Disability and Ageing (PBS)	Canberra	Government	PBS administration, PBAC secretariat and listing instruments	The Commonwealth purchaser: PBAC recommends, the Department lists, and 2024–25 government spend of AUD 19.1 billion is the pool every originator is competing for.
03	CSL Limited	Melbourne	Local	Plasma-derived therapies, iron and global biotech	ASX-listed global plasma company and Australia’s most valuable life-sciences group; the domestic champion ministers cite when they talk about sovereign biologics.
04	CSL Seqirus	Melbourne	Local	Influenza and other vaccines for Australia and export	CSL’s vaccine arm, with Australian manufacturing that supplies the national influenza programme and export contracts — a separate account from plasma.
05	Mayne Pharma	Salisbury	Local	Generics, specialty brands and contract development	ASX-listed South Australian manufacturer that is the local generics name most often paired with Viatris when a PBS price-disclosure story is being told.
06	Viatris (Alphapharm)	Carole Park	MNC	PBS generics and the historic Alphapharm manufacturing site	Viatris’s Australian generics franchise, still widely known as Alphapharm, is the plant and the brand that originators watch when a molecule goes off patent.
07	Pfizer Australia	Sydney	MNC	Vaccines, oncology, anti-infectives and hospital specialty	Innovator affiliate with both a PBS-listed specialty book and a manufacturing history that still comes up in sovereign-capability debates.
08	GSK Australia	Melbourne	MNC	Vaccines, respiratory, HIV and specialty	Vaccine and respiratory affiliate whose PBS and National Immunisation Program listings are as commercially important as its private pharmacy brands.
09	AstraZeneca Australia	Sydney	MNC	Oncology, cardiovascular, respiratory and rare disease	High-value PBS oncology and respiratory franchise; a reference account for how a global specialty brand survives price disclosure and biosimilar entry.
10	Novartis Australia	Sydney	MNC	Cardiovascular, oncology, immunology and ophthalmology	Specialty affiliate whose PBAC history — including high-cost gene and radioligand therapies — is a case library for any first-in-class access plan.
11	Roche Australia	Sydney	MNC	Oncology, diagnostics and immunology	Oncology affiliate whose listings and managed-access deeds are studied whenever a client asks how PBAC treats a high-cost biologic.
12	Sanofi Australia	Macquarie Park	MNC	Specialty, vaccines, rare disease and consumer health	Dual-track affiliate: PBS specialty and immunisation on one side, pharmacy consumer health on the other.
13	MSD Australia	Sydney	MNC	Oncology, vaccines, antivirals and hospital products	Keytruda and vaccine listings make MSD one of the largest PBS counterparties by value in recent years.
14	Janssen Australia	Sydney	MNC	Oncology, immunology, neuroscience and pulmonary hypertension	Johnson & Johnson’s medicines affiliate; another high-cost PBS specialty book that hospital P&T committees see constantly.
15	Amgen Australia	Sydney	MNC	Oncology, bone health and inflammatory specialty biologics	Biotech affiliate whose PBS and hospital-formulary work is a clean example of a company with almost no retail OTC story.
16	Bristol Myers Squibb Australia	Melbourne	MNC	Oncology, haematology and cardiovascular specialty	Innovator affiliate concentrated on PBS oncology and haematology, often paired with Roche and MSD in hospital share-of-voice studies.
17	Aspen Pharmacare Australia	Sydney	Regional	Established brands, hospital injectables and licensed portfolios	South African group’s Australian company, holding a large book of mature brands and hospital products that sit below the specialty-originator tier.
18	Sigma Healthcare	Melbourne	Distributor	Full-line wholesale into community pharmacy after the Chemist Warehouse combination	The wholesale-and-retail group whose depot and banner decisions now sit beside PBS listing as a practical ranging gate for community products.

Primary research

These are the pharmaceutical companies accounts we study in Australia

Need account-level or SKU-level data for a brand in Australia? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Australia?

Primary research, market access & HEOR. Proposals within 48 hours.

Top pharmaceutical market research companies in Australia (2026)

How the market is structured

How TGA registration and PBS listing decide whether a medicine is commercially real

Every prescription product needs an ARTG entry. TGA offers standard, priority and provisional pathways and participates in the Access Consortium with the UK, Canada, Singapore and Switzerland; many dossiers now ride on FDA or EMA reviews. Registration is not reimbursement. A sponsor then files with PBAC, which applies cost-effectiveness analysis — informal bands often described around AUD 45,000–75,000 per QALY, with separate logic for the Life Saving Drugs Program — and recommends a listing, a deferral or a rejection. Price disclosure on the PBS forces subsequent cuts when actual dispensed prices fall, which is why generic and biosimilar houses such as Viatris/Alphapharm and Mayne can erode an originator’s net even after a successful listing. Community pharmacies dispense most Section 85 products; hospitals administer Section 100 and highly specialised drugs under state formularies that generally follow, but sometimes trail, the PBS. Private health insurance, held by a large minority of Australians, pays hospital episodes and devices more than it pays outpatient medicines, so it is not a second PBS. CSL’s Broadmeadows and Parkville sites, Seqirus’s vaccine plants, and Alphapharm’s Queensland factory are the manufacturing names that come up when a minister talks about sovereign capability; most innovator volume is still imported by the affiliates and distributed through full-line wholesalers into Chemist Warehouse, TerryWhite Chemmart, Priceline and independent pharmacies. Medicines Australia is the industry body that negotiates the Strategic Agreement with government; it is not a company on this list because it does not manufacture, reimburse or dispense.

Local

CSL and Seqirus as the global plasma and vaccine champion, plus Mayne Pharma as the ASX-listed generics manufacturer based in South Australia.

CSL Limited
CSL Seqirus
Mayne Pharma

Multinational

Innovator affiliates and Viatris/Alphapharm, whose PBS oncology, immunology and off-patent books account for most high-value subsidised spend.

Viatris (Alphapharm)
Pfizer Australia
GSK Australia
AstraZeneca Australia
Novartis Australia
Roche Australia
Sanofi Australia
MSD Australia
Janssen Australia
Amgen Australia
Bristol Myers Squibb Australia

Regional

Aspen and other non-European, non-US groups that hold mature Australian portfolios or hospital injectables rather than first-in-class launches.

Aspen Pharmacare Australia

Distributors & importers

TGA, the PBS-administering Department, and Sigma Healthcare, whose registration, listing and wholesale decisions decide whether a SKU is commercially real.

Therapeutic Goods Administration (TGA)
Department of Health, Disability and Ageing (PBS)
Sigma Healthcare

What is moving

What is moving the pharmaceutical market in Australia

PBS listing as the real launch

With government spend at AUD 19.1 billion and a AUD 25 general copay, a medicine that misses PBAC will not see national volume. Sponsors now sequence TGA and PBAC in parallel and budget for deeds, risk-sharing and resubmissions rather than for a single “yes.”

Price disclosure and biosimilar erosion

Mandatory disclosure keeps cutting net prices after listing, and biosimilar and generic houses — Viatris/Alphapharm, Mayne, and hospital-preferred brands — take unit share quickly. Originator forecasts have to assume a steeper cliff than in markets without a PBS-style disclosure cycle.

CSL as a sovereign biologics and vaccine platform

Plasma therapies and Seqirus influenza capacity give Australia a domestic manufacturing story that ministers will keep funding. That does not replace imported specialty, but it does change how government talks about onshore fill-finish and about who is a strategic supplier.

Community-pharmacy concentration after banner consolidation

Chemist Warehouse, Sigma and the remaining banners now concentrate ranging decisions. A PBS listing still creates the subsidy; a banner decision decides whether the pack is actually on the shelf in Sydney, Melbourne and Brisbane.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Australia

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Australia:

PBAC outcome and PBS listing reconstructions by molecule for oncology, immunology and cardiometabolic classes, including deeds and price-disclosure steps after listing.
Hospital P&T interviews in Sydney, Melbourne and Brisbane on whether a new PBS item is actually stocked, and how fast a biosimilar is preferred.
Community-pharmacy banner and independent interviews on ranging after the Sigma–Chemist Warehouse combination, focused on chronic-care and vaccine SKUs.
CSL and Seqirus supply-side interviews treating plasma and influenza capacity as an industrial file separate from innovator-affiliate share-of-voice.

Healthcare market research in Australia

Questions

Frequently Asked Questions

Which pharmaceutical companies are most important in Australia?

CSL and Seqirus are the domestic global players. On PBS value, MSD, Pfizer, AstraZeneca, Novartis, Roche, Janssen, Amgen and Bristol Myers Squibb recur at the top of specialty spend; Viatris/Alphapharm and Mayne matter once a molecule is off patent. Rankings shift with new listings and price disclosure.

Is TGA approval enough to sell at scale?

It is enough to sell privately. It is not enough to reach most patients. Without a PBS listing, the patient faces the full price, and community pharmacies will not dispense the product as a subsidised script. Hospital formularies generally follow the PBS for high-cost drugs.

What did the Commonwealth spend on the PBS in 2024–25?

AUD 19.1 billion of government money, 91.7% of total medicine cost on the scheme, up 7.4% on the previous year. Patients paid AUD 1.7 billion. Some 226 million subsidised prescriptions were dispensed, and 949 medicines were listed at 30 June 2025.

Why is CSL treated differently from other Australian companies?

It is a global plasma and vaccine group headquartered in Melbourne, not a domestic generics house. Seqirus supplies influenza vaccine from Australian sites. That combination makes CSL a sovereign-capability account as well as a commercial one, which is why it sits beside TGA and the Department on this page.

How does BioNixus research pharmaceutical companies in Australia?

PBAC and PBS history is reconstructed by molecule; hospital P&T interviews in Sydney, Melbourne and Brisbane test whether listing has become formulary practice; community-pharmacy banner interviews cover ranging after Sigma and Chemist Warehouse consolidation; plasma and vaccine supply conversations treat CSL and Seqirus as a separate industrial file.

Is this an official ranking of Australian pharmaceutical companies?

Nothing here is an official or unofficial ranking. Sponsors, the TGA register and PBS history explain why a name is present; BioNixus does not sort Australian companies by revenue or script volume.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Australia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: Therapeutic Goods Administration — Australian Register of Therapeutic Goods and licensed manufacturers, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Australia, not size.

PBS Expenditure and Prescriptions Report, 1 July 2024 to 30 June 2025, Department of Health, Disability and Ageing
TGA public materials on ARTG pathways and Access Consortium; PBAC public summary documents
ASX filings and reports for CSL, Mayne Pharma; Viatris/Alphapharm site materials
BioNixus Australia PBS, hospital-formulary and community-pharmacy fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Australia?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Australia?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Australia

Top pharmaceutical companies in Australia

These are the pharmaceutical companies accounts we study in Australia

Planning research in Australia?

How TGA registration and PBS listing decide whether a medicine is commercially real

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Australia

PBS listing as the real launch

Price disclosure and biosimilar erosion

CSL as a sovereign biologics and vaccine platform

Community-pharmacy concentration after banner consolidation

How BioNixus studies pharmaceutical companies in Australia

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Australia?

Planning research in Australia?